15-26岁女性阴道和外阴上皮内瘤变的人乳头瘤病毒基因型
该研究对两项3期随机HPV疫苗试验安慰剂组中15-26岁女性进行事后分析,随访约4年共8798人,诊断外阴LSIL 40例、HSIL 46例,阴道LSIL 118例、HSIL 33例;大多数病变可归因于分析的14种HPV基因型中的至少一种,有效免疫规划或可预防大量HPV相关外阴和阴道LSIL及HSIL。
要点
- 随访约4年,8798名女性中外阴LSIL 40例、HSIL 46例,阴道LSIL 118例、HSIL 33例。
- 外阴LSIL 72.5%、外阴HSIL 91.3%、阴道LSIL 61.9%、阴道HSIL 72.7%检测到至少1种分析的14种HPV基因型。
- 仅考虑HPV阳性病变,9种常见基因型(6、11、16、18、31、33、45、52、58)见于89.4%外阴LSIL、100%外阴HSIL、56.0%阴道LSIL、78.3%阴道HSIL。
核心结论
- 大多数外阴和阴道病变可归因于分析的14种HPV基因型中的至少1种。
- 有效免疫规划或可预防大量HPV相关外阴和阴道LSIL及HSIL。
研究设计与样本
- 两项3期随机HPV疫苗试验安慰剂组的事后分析,纳入15-26岁女性,前瞻性诊断外阴和阴道LSIL及HSIL。
- 采用型特异性多重聚合酶链反应检测14种预设HPV基因型(6、11、16、18、31、33、35、39、45、51、52、56、58、59)。
- 随访约4年,共8798名女性。
主要发现
- 外阴LSIL 40例、外阴HSIL 46例,诊断于68名女性;阴道LSIL 118例、阴道HSIL 33例,诊断于107名女性。
- 发生外阴病变的女性中41.2%、发生阴道病变的女性中49.5%同时有宫颈病变;有宫颈病变的女性中6.5%有阴道或外阴病变。
- 外阴LSIL中72.5%、外阴HSIL中91.3%、阴道LSIL中61.9%、阴道HSIL中72.7%检测到至少1种分析的14种HPV基因型。
- 仅考虑HPV阳性病变,9种常见基因型(6、11、16、18、31、33、45、52、58)见于89.4%外阴LSIL、100%外阴HSIL、56.0%阴道LSIL、78.3%阴道HSIL。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate the proportion of vulvar and vaginal low-grade and high-grade squamous intraepithelial lesions (LSILs and HSILs) in females 15-26 years of age attributable to 14 human papillomavirus (HPV) genotypes (6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59). METHODS: A post hoc analysis of prospectively diagnosed vulvar and vaginal LSILs and HSILs among females 15-26 years of age enrolled in the placebo arms of two phase 3, randomized HPV vaccine trials assessed 14 prespecified HPV genotypes associated with cervical cancers or anogenital warts using a type-specific multiplex polymerase chain reaction assay. The frequency of lesions associated with specific HPV genotypes was estimated by proportional and other attribution methods. RESULTS: During approximately 4 years of follow-up in 8,798 females, 40 vulvar LSILs and 46 vulvar HSILs were diagnosed in 68 females, and 118 vaginal LSILs and 33 vaginal HSILs were diagnosed in 107 females. Females developing vulvar (41.2%) or vaginal (49.5%) lesions also had cervical lesions, whereas 6.5% of females with cervical lesions had vaginal or vulvar lesions. At least 1 of the 14 HPV genotypes was detected in females with vulvar LSIL (72.5%), vulvar HSIL (91.3%), vaginal LSIL (61.9%), and vaginal HSIL (72.7%). Considering only HPV-positive lesions, the nine most common genotypes causing cervical cancer and anogenital warts (6, 11, 16, 18, 31, 33, 45, 52, and 58) were found in 89.4% of vulvar LSILs, 100% of vulvar HSILs, 56.0% of vaginal LSILs, and 78.3% of vaginal HSILs. CONCLUSION: Most vulvar and vaginal lesions were attributable to at least 1 of the 14 HPV genotypes analyzed. Effective immunization programs could potentially prevent substantial numbers of HPV-related vulvar and vaginal LSILs and HSILs. CLINICAL TRIAL REGISTRATION: CLINICALTRIALS.GOV,: NCT00092521 and NCT00092534.
引用
- Garland SM, Joura EA, Ault KA, et al. Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of Age. Obstet Gynecol. 2018. PMID: 29995724. doi:10.1097/AOG.0000000000002736
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。